An altered gut microbiome has been implicated in Parkinson’s disease (PD), yet its reciprocal effects on systemic metabolism remain unclear. This cross-sectional study included 67 PD patients and 64 non-PD controls and integrated untargeted serum and fecal metabolomics using liquid chromatography-mass spectrometry with 16S rRNA gene sequencing of the gut microbiome. PD patients exhibited lipid dysregulation, including alterations in serum isoprenoids and their bacteria-derived precursor (2-C-methyl- D -erythritol 4-phosphate), sphingolipids, and glycerophospholipids, with perturbations in fatty acid biosynthesis pathways. Multi-omics integration revealed that PD was more closely associated with gut microbiome and serum metabolomics. Serum N -hydroxy- L -phenylalanine was linked to hydrogen sulfide-producing Desulfovibrio , implicating microbial-related amino acid metabolism. Machine learning models predicted cognition in PD more robustly than motor impairment and were driven exclusively by gut-derived features, including short-chain fatty acid-producing taxa, opportunistic pathogens, and fecal lipid metabolites, whereas no serum metabolites contributed. These findings highlight novel microbial-driven lipid and amino acid pathways with potential biomarker and therapeutic relevance in PD.
No takes yet. Share an insight, caveat, or question.
Toh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: